Chairman and Chief Executive, Kite Pharma
Arie Belldegrun has been a leader in developing novel cancer treatments. He has also been closely involved with the founding and advancement of several successful private and public biopharmaceutical companies. He founded Agensys Inc., a biotechnology company, in 1996 and served as its chairman and a board member until 2007 when it was acquired by Astellas Pharma Inc. He is also chairman of Arno Therapeutics, Two River Group, and UroGen Pharma. He is a board member of Cell Design Labs and a member of the Parker Institute for Cancer Immunotherapy’s Strategic Advisory Group. Belldegrun is also a professor of urology and is director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine.